|Bid||1,429.60 x 175400|
|Ask||1,429.80 x 417900|
|Day's Range||1,412.53 - 1,432.00|
|52 Week Range||1,236.40 - 1,724.50|
|PE Ratio (TTM)||46.12|
|Earnings Date||Apr 25, 2018|
|Forward Dividend & Yield||0.80 (5.63%)|
|1y Target Est||1,523.91|
A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.
-Preclinical testing raises no safety concerns for MAGE A4-- Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity-. PHILADELPHIA, Pa. and OXFORD, United ...
Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.
U.K. stocks struggle for direction on Thursday, as investors remain nervous over the potential for a military conflict in Syria and digested the latest Federal Reserve minutes.
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
Both of these pharmaceutical giants are trading at cheap valuations and offer big dividends, due to troubles that are mostly behind them.
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
Given the increase in population and incidence of diseases along with growing awareness and healthcare coverage initiatives, the drug sector is expected to grow.
A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.
As GlaxoSmithKline (GSK) starts a strategic review of Horlicks and other smaller nutrition products, a number of companies in the food & beverage industry are waiting to scoop it up.
GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base. The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
GlaxoSmithKline agreed to pay Novartis $13 billion for its 36.5% stake in their consumer health-care joint venture, moving to consolidate the unit just three years after the two companies joined forces....
On a day stocks sold off, GlaxoSmithKline announced it is buying out Novartis' share of a joint venture, and Red Hat reported a strong quarter.
GlaxoSmithKline will spend $13 billion to buy out Novartis' 36.5% stake in its consumer health unit in a transaction expected to close in the second quarter.
Food giants Nestle , Kraft Heinz and Unilever are expected to bid for GlaxoSmithKline's Horlicks health nutrition business, which could fetch more than $4 billion, according to people familiar with the ...
FRANKFURT/ZURICH (Reuters) - GlaxoSmithKline (LSE:GSK.L - News) is buying Novartis (:NOVN.S) out of their consumer healthcare joint venture for $13 billion, taking full control of products including Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren, and Nicotinell patches. GSK's biggest move since Emma Walmsley became chief executive last year follows the British drugmaker's decision last week to quit the race to buy Pfizer's (:PFE - News) consumer healthcare business, endangering an auction the U.S. company hoped would bring in as much as $20 billion. "The proposed transaction addresses one of our key capital allocation priorities and will allow GSK shareholders to capture the full value of one of the world's leading consumer healthcare businesses," Walmsley said in a statement on Tuesday.
NEW YORK, March 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...